|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2002-10-9
|
|
pubmed:abstractText |
The ultrashort-acting benzodiazepine (USA BZD) agonists reported previously have been structurally modified to improve aqueous solubility. Lactam-to-amidine modifications, replacement of the C5-haloaryl ring, and annulation of heterocycles are presented. These analogues retain BZD receptor potency and full agonism profiles.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:CowanJill RJR,
pubmed-author:CoxRichard FRF,
pubmed-author:DorseyGeorge FGFJr,
pubmed-author:FeldmanPaul LPL,
pubmed-author:GonzalesStephen SSS,
pubmed-author:KaldorIstvanI,
pubmed-author:KoszalkaGeorge WGW,
pubmed-author:LovellGeorge GGG,
pubmed-author:McIntyreMaggie SMS,
pubmed-author:PacofskyGregory JGJ,
pubmed-author:StaffordJeffrey AJA,
pubmed-author:TidwellJeffrey HJH,
pubmed-author:ToddDanD,
pubmed-author:WhitesellGrahamG,
pubmed-author:WiardRobert PRP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3219-22
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Relating the structure, activity, and physical properties of ultrashort-acting benzodiazepine receptor agonists.
|
|
pubmed:affiliation |
GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709, USA.
|
|
pubmed:publicationType |
Journal Article
|
